Utilization of dialkylfumarates
View Patent ↗The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
1. A method of treating autoimmune polyarthritis but not treating psoriatic arthritis, comprising administering, to a patient in need of treatment for said polyarthritis but not for said psoriatic arthritis, an amount of a pharmaceutical preparation effective for treating said polyarthritis, the pharmaceutical preparation comprising
at least one excipient or at least one carrier or a combination thereof and
an active ingredient only consisting of dimethyl fumarate, methyl hydrogen fumarate, or a combination thereof.
2. The method of claim 1 , wherein 10 mg to 300 mg of the active ingredient is administered.
3. The method of claim 1 , wherein the active ingredient is provided in one or more capsules.
4. The method of claim 1 , wherein the active ingredient consists of 50 mg of dimethyl fumarate.
5. The method of claim 1 , wherein the active ingredient consists of 110 mg of dimethyl fumarate.
6. The method of claim 1 , wherein the active ingredient consists of 120 mg of dimethyl fumarate.
7. The method of claim 1 , wherein the active ingredient consists of methyl hydrogen fumarate.
8. The method of claim 7 , wherein the active ingredient consists of 10 mg to 300 mg of methyl hydrogen fumarate.
9. The method of claim 1 , wherein the active ingredient consists of dimethyl fumarate.
10. The method of claim 9 , wherein the active ingredient consists of 10 mg to 300 mg of dimethyl fumarate.
11. The method of claim 9 , wherein the active ingredient consists of 50 mg of dimethyl fumarate.
12. The method of claim 9 , wherein the active ingredient consists of 110 mg of dimethyl fumarate.
13. The method of claim 9 , wherein the active ingredient consists of 120 mg of dimethyl fumarate.
14. The method of claim 1 , wherein the pharmaceutical preparation is formulated for oral administration.
15. The method of claim 1 , wherein the pharmaceutical preparation is formulated as a solid dosage form.
16. The method of claim 1 , wherein the pharmaceutical preparation is in the form of microtablets.
17. The method of claim 16 , wherein the microtablets are provided in one or more capsules, each capsule containing at least 50 mg of dimethyl fumarate.
18. The method of claim 17 , wherein each capsule contains at least 110 mg of dimethyl fumarate.
19. The method of claim 18 , wherein each capsule contains at least 120 mg of dimethyl fumarate.
20. The method of claim 16 , wherein the microtablets are enteric-coated.
21. The method of claim 16 , wherein the microtablets have a mean diameter in the range of 0.3 mm to 2.0 mm, exclusive of any coating on the microtablets.
22. The method of claim 21 , wherein the microtablets have a mean diameter of 2.0 mm, exclusive of any coating on the microtablets.
23. The method of claim 1 , wherein the active ingredient consists of at least 50 mg of dimethyl fumarate.
24. The method of claim 1 , wherein the active ingredient consists of at least 110 mg of dimethyl fumarate.
25. The method of claim 1 , wherein the active ingredient consists of at least 120 mg of dimethyl fumarate.
26. The method of claim 1 , wherein the pharmaceutical preparation comprises at least one carrier.
27. The method of claim 1 , wherein the pharmaceutical preparation comprises at least one excipient.
28. The method of claim 1 , wherein the active ingredient consists of only both dimethyl fumarate and methyl hydrogen fumarate.
29. The method of claim 1 , wherein the pharmaceutical preparation comprises at least one excipient and at least one carrier.